Infection Risk Plummets? Shocking Truth from 60,000-Eye Study on Cataract Surgery скачать в хорошем качестве

Infection Risk Plummets? Shocking Truth from 60,000-Eye Study on Cataract Surgery

Hello, I am Dr. Takahashi, an ophthalmologist. This time, I'm bringing you vital, cutting-edge information on "postoperative infection (endophthalmitis) prevention," crucial for both patients undergoing cataract surgery and ophthalmic medical professionals. In the latter half of 2025, a paper was published that has made a significant impact on the ophthalmology industry. It is the result of a *large-scale clinical study (RCT) involving 60,000 eyes* conducted in India. The theme is "Intracameral Moxifloxacin Injection." How much does this method of directly injecting antibiotics into the eye at the end of surgery reduce the risk of infection? How does it compare to just using traditional eye drops? Are there any safety concerns? These questions have been answered with an overwhelming amount of data. In this video, based on the latest data from the JCRS journal, I will explain clearly why this method could become the future "Standard of Care." If you are preparing for surgery or want to know about the latest medical circumstances, please watch until the end. ─────────────── ▼Subscribe here    / @stvisualrevolution   ▼Second Channel (Dr.Talk - Oph)    / @drstalk-oph   ─────────────── 【Video Highlights】 ・**Endophthalmitis risk reduced by approximately 2.5 times**: The incidence rate significantly decreased from 0.05% to 0.02%. ・**High safety profile**: No significant effects on corneal endothelial cells or risks of side effects like TASS (Toxic Anterior Segment Syndrome) were observed. ・**Improved medical safety**: Using a formulation that does not require dilution avoids risks of preparation errors and contamination. To put it metaphorically, this method is like **"placing elite guards directly inside the building (intracameral injection)"**, instead of just "having guards check at the building entrance (postoperative eye drops)." It is a highly rational defense strategy that leaves no room for bacteria to proliferate. ─────────────── 【References/Citations】 Journal of Cataract and Refractive Surgery (JCRS), October 2025 issue. "Intracameral moxifloxacin for endophthalmitis prophylaxis: A randomized clinical trial of 60,000 eyes" ─────────────── #CataractSurgery #Endophthalmitis #Moxifloxacin #Vigamox #Ophthalmology #LatestMedicalNews #MedicalJournal #SurgicalSafety #RCT #InfectionControl